Viral vectors and methods for producing and using the same

Details Viral vectors and methods for producing and using the same Viral vectors and methods for producing and using the same

2003-04-30

2010-12-28

Sajjadi, Fereydoun G (Department: 1633)

Chemistry: molecular biology and microbiology

Vector, per se

C435S235100, C424S093200

Reexamination Certificate

active

07858367

ABSTRACT:
A recombinant hybrid virus which includes: (a) a deleted adenovirus vector genome having the adenovirus 5′ and 3′ cis-elements for viral replication and encapsidation and a deletion in an adenovirus genomic region selected from the polymerase region and/or the preterminal protein region, wherein the deletion essentially prevents the expression of a functional polymerase and/or preterminal protein from the deleted region and the hybrid virus does not otherwise express a functional polymerase protein; and (b) a recombinant adeno-associated virus (AAV) vector genome flanked by the adenovirus vector genome sequences of (a), wherein the recombinant AAV vector genome includes an AAV packaging sequence and a heterologous nucleic acid sequence, wherein the heterologous nucleic acid sequence is flanked by 5′ and 3′ AAV inverted terminal repeats.

REFERENCES:
patent: 4501729 (1985-02-01), Boucher et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5712136 (1998-01-01), Wickham et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 5861156 (1999-01-01), George et al.
patent: 5869248 (1999-02-01), Yuan et al.
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5872005 (1999-02-01), Wang et al.
patent: 5877022 (1999-03-01), Stinchcomb et al.
patent: 5922315 (1999-07-01), Roy et al.
patent: 5962313 (1999-10-01), Podsakoff et al.
patent: 6013487 (2000-01-01), Mitchell
patent: 6083702 (2000-07-01), Mitchell et al.
patent: 6156303 (2000-12-01), Russell et al.
patent: 6251677 (2001-06-01), Wilson et al.
patent: 6258595 (2001-07-01), Gao et al.
patent: 6270996 (2001-08-01), Wilson et al.
patent: 6294370 (2001-09-01), Bogedain et al.
patent: 6329181 (2001-12-01), Xiao et al.
patent: 6329958 (2001-12-01), McLean et al.
patent: 6383794 (2002-05-01), Mountz et al.
patent: 2003/0017139 (2003-01-01), Souza et al.
patent: WO90/05142 (1990-05-01), None
patent: WO 00/11149 (2000-03-01), None
patent: WO 02/063025 (2002-08-01), None
Lieber et al. J. Virol. 73(11):9314-9324; 1999.
Samulski et al. J. Virol. 63(9):3822-3828; 1989.
Lieber et al., Integrating Adenovirus-Adeno-Associated Virus Hybrid Vectors Devoid of all Viral Genes,J. of Virology73(11):9314-9324 (Nov. 1999).
Pauley et al., Intercellular Transfer of the Virally Derived Precursor Form of Acid α-Glucosidase Corrects the Enzyme Deficiency in Inherited Cardioskelatal Myopathy Pompe Disease,Human Gene Therapy12:527-538 (Mar. 20, 2001).
Ding et al., Long-Term Efficacy after [E1 , polymerase] Adenovirus-Mediated Transfer of Human Acid-α-Glucosidase Gene into Glycogen Storage Disease Type II Knockout Mice,Human Gene Therapy12:955-965 (May 20, 2001).
Sun et al., Long-Term Correction of Glycogen Storage Disease Type II with a Hybrid Ad-AAV Vector,Molecular Therapy7(2):193-201 (Feb. 2003).
Notification of Transmittal of the International Search Report for PCT/US03/13323 dated Aug. 2, 2004.
Written Opinion for PCT/US03/13323 dated Oct. 19, 2004.
International Preliminary Examination Report corresponding to PCT App. No. PCT/US03/13323 dated Apr. 7, 2005.
Allen et al., “Improved Adeno-Associated Virus Vector Production with Transfection of a Single Helper Adenovirus Gene, E4orf6,” Mol. Ther., vol. 1, pp. 88-95 (2000).
Amalfitano et al., “Production and Characterization of Improved Adenovirus Vectors with the E1, E2b, and E3 Genes Deleted,” J. Virol., vol. 72, pp. 926-933 (1998).
Amalfitano et al., “Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-α-glucosidase,” PNAS, vol. 96, pp. 8861-8866 (1999).
Gao et al., “High-Titer Adeno-Associated Viral Vectors from a Rep/Cap Cell Line and Hybrid Shuttle Virus,” Hum. Gene Ther., vol. 9, pp. 2353-2362 (1998).
Gao et al., “Rep/Cap Gene Amplification and High-Yield Production of AAV in an A549 Cell Line Expressing Rep/Cap,” Mol. Ther., vol. 5, pp. 644-649 (2002).
He et al., “A simplified system for generating recombinant adenoviruses,” PNAS, vol. 95, pp. 2509-2514 (1998).
Hodges et al., “Multiply deleted [E1, polymerase-, and pTP-] adenovirus vector persists despite deletion of the preterminal protein,” J. Gene Med., vol. 2, pp. 250-259 (2000).
Lieber et al., “Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo,” J. Virol., vol. 70, pp. 8944-8960 (1996).
Liu et al., “Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus,” Gene Ther., vol. 6, pp. 293-299 (1999).
Muzyczka, N., “Use of adeno-associated virus as a general transduction vector for mammalian cells,” Current Topics in Microbiology and Immunology, vol. 158, pp. 97-129 (1992).
Sun et al., “Packaging of an AAV Vector Encoding Human Acid α-Glucosidase for Gene Therapy in Glycogen Storage Disease Type II with a Modified Hybrid Adenovirus-AAV Vector,” Mol. Ther., vol. 7, pp. 467-477 (2003).
Van Hove et al., “High-level production of recombinant human lysosomal acid a-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease,” PNAS, vol. 93, pp. 65-70 (1996).
Weitzman et al., “Recruitment of wild-type and recombinant adeno-associated virus into adenovirus replication centers,” J. Virol., vol. 70, No. 3, pp. 1845-1854 (1996).
Zhang et al., “Recombinant adenovirus expressing adeno-associtated virus cap and rep proteins supports production of high-titer recombinant adeno-associated virus,” Gene Ther., vol. 8, pp. 704-712 (2001).
Allen et al., “Identification and Elimination of Replication-Competent Adeno-Associated Virus (AAV) That Can Arise by Nonhomologous Recombination during AAV Vector Production,” Journal of Virology. vol. 71, No. 9 pp. 6816-6822 (1997).
Conway et al., “High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap,” Gene Therapy. vol. 6 pp. 986-993 (1999).
Coulie et al., “A New Gene Coding for a Differentiation Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas,” Journal of Experimental Medicine. vol. 180 pp. 35-42 (1994).
Daly et al., “Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease,” PNAS. vol. 96 pp. 2296-2300 (1999).
Franco et al., “Evasion of Immune Response to Introduced Human Acid α-Glucosidase by Liver-Restricted Expression in Glycogen Storage Disease Type II,” Molecular Therapy. vol. 12, No. 5 pp. 876-884 (2005).
Gorman et al., “Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs,” PNAS. vol. 95 pp. 4929-4934 (1998).
Hoefsloot et al., “Primary structure and processing of lysosomal α-glucosidase; homology with the intestinal sucrase—isomaltase complex,” The EMBO Journal. vol. 7, No. 6 pp. 1697-1704 (1988).
Inoue, N., and Russell, D.W., “Packaging Cells Based on Inducible Gene Amplification for the Production of Adeno-Associated Virus Vectors,” Journal of Virology. vol. 72, No. 9 pp. 7024-7031 (1998).
Jung et al., “Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice,” PNAS. vol. 98, No. 5 pp. 2676-2681 (2001).
Kawakami et al., “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor,” PNAS. vol. 91 pp. 3515-3519 (1994).
Kawakami et al., “Identifica

Affiliated with

Also associated with

Rating

Viral vectors and methods for producing and using the same does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Viral vectors and methods for producing and using the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Viral vectors and methods for producing and using the same will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4157562